Table 5.
Demographic profile of patients and phenotypic antimicrobial susceptibility among 49 carbapenem-resistant P. aeruginosa and 48 CREs isolates collected between 2017 and 2019. Sites of isolation: respiratory tract (RT), intrabdominal (IA), urinary tract UT, blood stream (BS)
| Species | Pseudomonas aeruginosa | Klebsiella pneumoniae | Escherichia coli | Enterobacter cloacae | Serratia marcescens | Klebsiella variicola | Klebsiella aerogenes | Total (%) |
|---|---|---|---|---|---|---|---|---|
| Gender | Number (%) | |||||||
| Male | 37 (75.51) | 20 (74.07) | 5 (44.45) | 1 (25) | 3 (100) | 2 (100) | 1 (100) | 69 (71.13) |
| Female | 12 (24.49) | 7 (25.93) | 6 (54.55) | 3 (75) | 0 | 0 | 0 | 28 (28.87) |
| Location | ||||||||
| In-patient | 27 (55.1) | 21 (77.78) | 8 (72.73) | 3 (75) | 0 | 0 | 0 | 59 (60.82) |
| Intensive care unit | 22 (44.9) | 6 (22.22) | 3 (27.27) | 1 (25) | 3 (100) | 2 (100) | 1 (100) | 38 (39.18) |
| Age | ||||||||
| Paediatric < 14 years | 2 (4.08) | 1 (3.7) | 0 | 0 | 0 | 0 | 0 | 3 (3.09) |
| Adult 14-65 years | 31 (63.27) | 15 (55.56) | 8 (72.73) | 3 (75) | 3 (100) | 2 (100) | 1 (100) | 63 (64.95) |
| Geriatric > 65 | 16 (32.65) | 8 (29.63) | 3 (27.27) | 1 (25) | 0 | 0 | 0 | 28 (28.87) |
| Site of isolation | ||||||||
| RT | 36 (73.47) | 11 (40.74) | 0 | 1 (25) | 3 (100) | 1 (50) | 1 (100) | 53 (54.64) |
| IA | 5 (10.2) | 5 (18.52) | 6 (54.55) | 1 (25) | 0 | 1 (50) | 0 | 18 (18.56) |
| UT | 2 (4.08) | 7 (25.93) | 5 (45.45) | 2 (50) | 0 | 0 | 0 | 16 (16.49) |
| BS | 6 (12.24) | 4 (14.81) | 0 | 0 | 0 | 0 | 0 | 10 (10.31) |
| No. of isolates susceptible to | ||||||||
| Aztreonam | 14 (28.57) | 9 (33.33) | 0 | 1 (25) | 3 (100) | 2 (100) | 1 (100) | |
| Cefepime | 28 (57.14) | 5 (18.52) | 0 | 2 (50) | 2 (66.67) | 2 (100) | 1 (100) | |
| Cefotaxime | NA | 10 (37.04) | 0 | 2 (50) | 3 (100) | 2 (100) | 1 (100) | |
| Ceftazidime | 24 (48.98) | 6 (22.22) | 0 | 1 (25) | 3 (100) | 2 (100) | 0 | |
| Ceftriaxone | NA | 5 (18.52) | 0 | 1 (25) | 2 (66.67) | 2 (100) | 0 | |
| Colistin | 49 (100) | NA | NA | NA | NA | NA | NA | |
| Meropenem | 8 (16.33) | 4 (14.81) | 3 (27.27) | 2 (50) | 2 (66.67) | 1 (50) | 1 (100) | |
| Ertapenem | NA | 1 (3.7) | 0 | 1 (25) | 2 (66.67) | 0 | 1 (100) | |
| Imipenem | 0 | 2 (7.41) | 3 (27.27) | 1 (25) | 0 | 0 | 0 | |
| Ceftolozane/tazobactam | 41 (83.67) | 5 (18.52) | 1 (9.09) | 1 (25) | 2 (66.67) | 2 (100) | 1 (100) | |
| Imipenem/relebactam | 35 (71.43) | 6 (22.22) | 5 (45.45) | 2 (50) | 0 | 0 | 1 (100) | |
| Pipracillin/tazobactam | 19 (38.78) | 2 (7.41) | 0 | 1 (25) | 2 (66.67) | 0 | 1 (100) | |
| Total (%) | 49 (100) | 27 (100) | 11 (100) | 4 (100) | 3 (100) | 2 (100) | 1 (100) | 97 (100) |